Table 8.

Variables Significantly Associated with OIs in the Study Groups

	OI n = 11	Non-OI n = 109	P Value
Group n (%)
Tx patients	8 (72.7)	22 (20.18)	< .001*
Non-Tx patients	3 (27.3)	87 (79.81)
Baseline eGFR (mL/min)	42.06 ± 15.65	72.86 ± 27.55	< .008*
Diabetes mellitus n (%)	8 (72.7)	31 (28.44)	.003*
eGFR at dx (mL/min)	36.28 ± 19.87	68.24 ± 30.94	.01*
IL-6 (pg/mL)	135.4 (1682-25)	23.3 (744.7-1)	.001*
MULBSTA score	13.3 ± 3.88	9.27 ± 3.94	.003*
AKI at admission n (%)	6 (54.5)	22 (20.18)	.01*
ICU admission	6 (54.5)	13 (11.92)	< .001*
Shock n (%)	6 (54.5)	5 (4.58)	< .001*
Ventilatory support/O2 therapy n (%)
High-flow nasal cannula O2	4 (50)	26 (74.28)	.001*
Non-invasive mechanical ventilation	0 (0)	7 (20)
Invasive mechanical ventilation	4 (50)	2 (5.72)
AKI during follow-up n (%)	6 (54.5)	9 (8.25)	< .001*
CVVHD/HD n (%)	2 (18.2)	3 (2.75)	.01*
Concomitant infection n (%)	6 (54.3)	27 (24.77)	.03*
COVID-19 pharmacologic therapy n (%)
Remdesevir	5 (45.5)	16 (15)	.01*
Final eGFR (mL/min)	45.35 ± 28.45	74.2 ± 29.59	.003*
Hospitalization time (d)	19 (61-7)	7 (90-1)	.001*
ICU time (d)	25 ± 7.92	12.21 ± 14.58	.02*
Logistic Regression Model.
	B	E.T.	P Value	Exp(B)	IC 95%
Basal eGFR (mL/min)	–0.097	0.042	.02	0.9	0.83-0.98
IL-6 (pg/mL)	0.005	0.002	.021	1	1-1.01
Coinfection at admission	–3.08	1.34	.02	0.046	0.003-0.63

R² Nagelkerke: 0.70.

AKI, acute kidney injury; B,unstandarddized regression weight; COPD, chronic obstructive pulmonary disease; CVVHD; eGFR, estimated glomerular filtration rate; E.T., standard Error; HD, hemodialysis; ICU, intensive care unit; CI, confidence interval; IL, interleukin; OI, opportunistic infection; Tx, transplant.

^⁎P < .05.